FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2554629079> ?p ?o ?g. }

• W2554629079 abstract "Background Rheumatoid arthritis (RA) patients frequently report concomitant comorbidities that could worsen their prognosis. Tumour necrosis factor inhibitors (TNFi), the most common biological agents used, have shown efficacy in RA patients, although use in RA patients with certain comorbidities warrant caution (1). Abatacept, a biologic agent with a different mechanism of action, inhibiting the co-stimulation of T-lymphocyte, has demonstrated differentiated safety profile (2), that could influence the biological agent prescribed in RA patients with some associated comorbidities Objectives To analyse differences in the frequency of baseline comorbidities in RA patients treated with abatacept compared with those treated with TNFi Methods Patients with RA recruited into the BIOBADASER 2.0 register from January 2008 to December 2014 and treated with abatacept or TNFi with comorbidities were selected. Comorbidity was defined as ≥1 of the following at initiation of biological therapy: ischemic heart disease; malignancy (except lymphoma); diabetes; chronic pulmonary obstructive disease (CPOD); smoking; hypercholesterolemia; hypertension; heart failure; renal failure; lymphoma; osteoporosis; Epstein Barr, hepatitis B or C virus infection; and others. We analysed the frequency of each comorbidity, and differences in the rate of baseline comorbidities in the two groups were compared using t-test Results From January 2008 to December 2014, 640 and 252 RA patients treated respectively with TNFi or abatacept were included in the BIOBADASER 2.0 register, of whom 51.6% had ≥1 comorbidity at baseline. Frequencies for every basal comorbidity described are shown in Table 1. There was a significantly higher rate of heart failure in abatacept than in TNFi patients. Other comorbidities showed no significant differences. Conclusions RA patients treated with abatacept had a higher baseline rate of concomitant heart failure compared with patients treated with TNFi, probably reflecting different recommendations on biological use. Even though abatacept has demonstrated a differentiated safety profile, overall no differences in other baseline comorbidities were found between groups References Singh et al. Arthritis Rheum 2016;68:1–26. Singh et al. Cochrane Database Syst Rev. 2011;16:CD008794 Disclosure of Interest None declared" @default.
• W2554629079 created "2016-11-30" @default.
• W2554629079 creator A5004662213 @default.
• W2554629079 creator A5011782353 @default.
• W2554629079 creator A5018199294 @default.
• W2554629079 creator A5020155471 @default.
• W2554629079 creator A5034589238 @default.
• W2554629079 creator A5041596944 @default.
• W2554629079 creator A5053496760 @default.
• W2554629079 creator A5054043059 @default.
• W2554629079 creator A5054338137 @default.
• W2554629079 creator A5054708705 @default.
• W2554629079 creator A5055676022 @default.
• W2554629079 creator A5065672404 @default.
• W2554629079 creator A5071926023 @default.
• W2554629079 date "2016-06-01" @default.
• W2554629079 modified "2023-10-17" @default.
• W2554629079 title "AB0278 Are There Differences in Basal Comorbidities between Rheumatoid Arthritis Patients Treated with Abatacept and Those Treated with Tumor Necrosis Factor Inhibitors?: Table 1" @default.
• W2554629079 doi "https://doi.org/10.1136/annrheumdis-2016-eular.4625" @default.
• W2554629079 hasPublicationYear "2016" @default.
• W2554629079 type Work @default.
• W2554629079 sameAs 2554629079 @default.
• W2554629079 citedByCount "0" @default.
• W2554629079 crossrefType "journal-article" @default.
• W2554629079 hasAuthorship W2554629079A5004662213 @default.
• W2554629079 hasAuthorship W2554629079A5011782353 @default.
• W2554629079 hasAuthorship W2554629079A5018199294 @default.
• W2554629079 hasAuthorship W2554629079A5020155471 @default.
• W2554629079 hasAuthorship W2554629079A5034589238 @default.
• W2554629079 hasAuthorship W2554629079A5041596944 @default.
• W2554629079 hasAuthorship W2554629079A5053496760 @default.
• W2554629079 hasAuthorship W2554629079A5054043059 @default.
• W2554629079 hasAuthorship W2554629079A5054338137 @default.
• W2554629079 hasAuthorship W2554629079A5054708705 @default.
• W2554629079 hasAuthorship W2554629079A5055676022 @default.
• W2554629079 hasAuthorship W2554629079A5065672404 @default.
• W2554629079 hasAuthorship W2554629079A5071926023 @default.
• W2554629079 hasConcept C126322002 @default.
• W2554629079 hasConcept C134018914 @default.
• W2554629079 hasConcept C143998085 @default.
• W2554629079 hasConcept C2777575956 @default.
• W2554629079 hasConcept C2779159551 @default.
• W2554629079 hasConcept C2779338263 @default.
• W2554629079 hasConcept C2779384505 @default.
• W2554629079 hasConcept C2779605438 @default.
• W2554629079 hasConcept C2780653079 @default.
• W2554629079 hasConcept C555293320 @default.
• W2554629079 hasConcept C71924100 @default.
• W2554629079 hasConceptScore W2554629079C126322002 @default.
• W2554629079 hasConceptScore W2554629079C134018914 @default.
• W2554629079 hasConceptScore W2554629079C143998085 @default.
• W2554629079 hasConceptScore W2554629079C2777575956 @default.
• W2554629079 hasConceptScore W2554629079C2779159551 @default.
• W2554629079 hasConceptScore W2554629079C2779338263 @default.
• W2554629079 hasConceptScore W2554629079C2779384505 @default.
• W2554629079 hasConceptScore W2554629079C2779605438 @default.
• W2554629079 hasConceptScore W2554629079C2780653079 @default.
• W2554629079 hasConceptScore W2554629079C555293320 @default.
• W2554629079 hasConceptScore W2554629079C71924100 @default.
• W2554629079 hasLocation W25546290791 @default.
• W2554629079 hasOpenAccess W2554629079 @default.
• W2554629079 hasPrimaryLocation W25546290791 @default.
• W2554629079 isParatext "false" @default.
• W2554629079 isRetracted "false" @default.
• W2554629079 magId "2554629079" @default.
• W2554629079 workType "article" @default.